FDA approves first treatment specifically for patients with rare and life-threatening type of immune disease - FDA Press Releases

The FDA approved Gamifant (emapalumab) for the treatment of pediatric (newborn and above) and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) who have refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. This FDA approval is the first for a drug specifically for HLH.

from Food and Drug Administration--Press Releases https://ift.tt/2PDb3lv
via IFTTT